## Sinchita Roy-Chowdhuri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6916086/publications.pdf

Version: 2024-02-01

123 papers 4,605

35 h-index 63 g-index

125 all docs

125 docs citations

125 times ranked 6480 citing authors

#	Article	IF	Citations
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. Journal of Clinical Pathology, 2023, 76, 47-52.	1.0	9
2	Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. Journal of Clinical Pathology, 2022, 75, 612-619.	1.0	11
3	Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathology, 2022, 130, 110-119.	1.4	12
4	Utility of SOX11 for the diagnosis of solid pseudopapillary neoplasm of the pancreas on cytological preparations. Cytopathology, 2022, 33, 216-221.	0.4	4
5	COVIDâ€19 pandemic impact on cytopathology practice in the postâ€lockdown period: An international, multicenter study. Cancer Cytopathology, 2022, 130, 344-351.	1.4	15
6	Editorial: Advances in Molecular Cytopathology. Frontiers in Medicine, 2022, 9, 851949.	1,2	2
7	Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. American Journal of Clinical Pathology, 2022, 158, 263-269.	0.4	7
8	Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial. Journal of Clinical Oncology, 2022, 40, 2224-2234.	0.8	45
9	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. Journal of Clinical Oncology, 2022, 40, 2235-2245.	0.8	21
10	Adequacy evaluation and use of pancreatic adenocarcinoma specimens for nextâ€generation sequencing acquired by endoscopic ultrasound–guided FNA and FNB. Cancer Cytopathology, 2022, 130, 275-283.	1.4	6
11	Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy. Archives of Pathology and Laboratory Medicine, 2021, 145, 46-54.	1.2	12
12	YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut, 2021, 70, 55-66.	6.1	53
13	A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Annals of Surgical Oncology, 2021, 28, 258-264.	0.7	39
14	Utilization of cytology smears improves success rates of RNAâ€based nextâ€generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathology, 2021, 129, 374-382.	1.4	22
15	Renal medullary carcinoma involving serous cavity fluids: a cytomorphologic study of 12 cases. Journal of the American Society of Cytopathology, 2021, 10, 187-196.	0.2	3
16	Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid in Patients with Central Nervous System Malignancies. Journal of Molecular Diagnostics, 2021, 23, 171-180.	1.2	20
17	Diagnostic value of digital droplet polymerase chain reaction and digital multiplexed detection of single-nucleotide variants in pancreatic cytology specimens collected by EUS-guided FNA. Gastrointestinal Endoscopy, 2021, 93, 1142-1151.e2.	0.5	5
18	The value of a tiered cytology diagnostic reporting system in assessing the risk of malignancy in indeterminate serous effusions. Cancer Cytopathology, 2021, 129, 75-82.	1.4	19

#	Article	IF	Citations
19	Cytomorphology of primary pulmonary NUT carcinoma in different cytology preparations. Cancer Cytopathology, 2021, 129, 53-61.	1.4	15
20	Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Archives of Pathology and Laboratory Medicine, 2021, 145, 1405-1412.	1.2	6
21	Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guidelines from the College of American Pathologists (CAP). Journal of Molecular Pathology, 2021, 2, 23-28.	0.5	0
22	A decade of change: Trends in the practice of cytopathology at a tertiary care cancer centre. Cytopathology, 2021, 32, 604-610.	0.4	4
23	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. Journal of Immunotherapy and Precision Oncology, 2021, 4, 45-52.	0.6	5
24	Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 207.	3.5	10
25	Cytologic Investigations for the Diagnosis of Malignant Pleural Effusion in Non–small Cell Lung Cancer. Journal of Bronchology and Interventional Pulmonology, 2021, 28, 310-321.	0.8	6
26	Modern Cytopathology: An evolving field. Cytopathology, 2021, 32, 560-561.	0.4	2
27	Advances in cytology of lung cancer. Seminars in Diagnostic Pathology, 2021, 38, 109-115.	1.0	7
28	Molecular Pathology of Lung Cancer. Surgical Pathology Clinics, 2021, 14, 369-377.	0.7	9
29	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature Medicine, 2021, 27, 141-151.	15.2	134
30	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. Npj Precision Oncology, 2021, 5, 99.	2.3	2
31	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut, 2020, 69, 18-31.	6.1	94
32	Detection of EGFR T790M Mutation by Droplet Digital Polymerase Chain Reaction in Lung Carcinoma Cytology Samples. Archives of Pathology and Laboratory Medicine, 2020, 144, 997-1002.	1.2	6
33	Tumorâ€derived cellâ€free DNA in body cavity effusion supernatants: A promising alternative for genomic profiling. Cancer Cytopathology, 2020, 128, 14-16.	1.4	5
34	Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer. Translational Lung Cancer Research, 2020, 9, 898-905.	1.3	15
35	Key Highlights for the College of American Pathology Statement on Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies. Chest, 2020, 158, 2282-2284.	0.4	1
36	Global impact of the COVIDâ€19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	1.4	47

#	Article	IF	Citations
37	Current and future trends in non–small cell lung cancer biomarker testing: The American experience. Cancer Cytopathology, 2020, 128, 629-636.	1.4	18
38	The world of molecular cytopathology: Predictive testing and precision medicine: Highlights from the eighth International Molecular Cytopathology Meeting in Naples, Italy. Cancer Cytopathology, 2020, 128, 599-600.	1.4	1
39	Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology, Archives of Pathology and Laboratory	1.2	65
40	Medicine, 2020, 144, 933-958.  Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors., 2020, 8, e000665.		8
41	A new guideline from the College of American Pathologists to improve the adequacy of thoracic small specimens for ancillary studies. Cancer Cytopathology, 2020, 128, 690-692.	1.4	1
42	Small but powerful: the promising role of small specimens for biomarker testing. Journal of the American Society of Cytopathology, 2020, 9, 450-460.	0.2	14
43	Primary pancreatic Ewing sarcoma: a cytomorphologic and histopathologic study of 13 cases. Journal of the American Society of Cytopathology, 2020, 9, 502-512.	0.2	6
44	Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World Journal of Surgical Oncology, 2020, 18, 39.	0.8	14
45	Diagnostic Molecular Pathology. , 2020, , 2145-2159.		O
46	Upfront molecular profiling of pancreatic cancer patients $\hat{a} \in \text{``An idea whose time has come.}$ Pancreatology, 2020, 20, 391-393.	0.5	8
47	Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Annals of Surgical Oncology, 2020, 27, 2806-2811.	0.7	13
48	#EBUSTwitter: Novel Use of Social Media for Conception, Coordination, and Completion of an International, Multicenter Pathology Study. Archives of Pathology and Laboratory Medicine, 2020, 144, 878-882.	1.2	11
49	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. Annals of the American Thoracic Society, 2020, 17, 550-554.	1.5	17
50	Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer, 2020, 20, 83.	1.1	10
51	EUS and EUS-guided FNA/core biopsies in the evaluation of subepithelial lesions of the lower gastrointestinal tract: 10-year experience. Endoscopic Ultrasound, 2020, 9, 329.	0.6	12
52	Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1521-1530.	0.6	94
53	Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. Journal of Surgical Oncology, 2019, 120, 1350-1357.	0.8	16
54	Bcl11b prevents catastrophic autoimmunity by controlling multiple aspects of a regulatory T cell gene expression program. Science Advances, 2019, 5, eaaw0706.	4.7	15

#	Article	IF	Citations
55	PD‣1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC. Respirology, 2019, 24, 1198-1203.	1.3	24
56	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	1.4	39
57	Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens. Annals of Oncology, 2019, 30, 963-969.	0.6	30
58	Invited reviewâ€"next-generation sequencing: a modern tool in cytopathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 3-11.	1.4	31
59	Becoming an Engaged Pathologist. Archives of Pathology and Laboratory Medicine, 2019, 143, 149-150.	1.2	2
60	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 699-714.	0.6	36
61	Displaced Cartilage Within Lymph Node Parenchyma Is a Novel Biopsy Site Change in Resected Mediastinal Lymph Nodes Following EBUS-TBNA. American Journal of Surgical Pathology, 2019, 43, 497-503.	2.1	10
62	Recommendations for Ancillary Testing. , 2019, , 125-142.		0
63	Centrifuged supernatants from FNA provide a liquid biopsy option for clinical nextâ€generation sequencing of thyroid nodules. Cancer Cytopathology, 2019, 127, 146-160.	1.4	37
64	Molecular testing of residual cytology samples: Rethink, reclaim, repurpose. Cancer Cytopathology, 2019, 127, 15-17.	1.4	20
65	Molecular Cytopathology: Final Thoughts and Future Directions. , 2019, , 517-528.		1
66	Molecular Cytopathology Correlations: Interpretation of Molecular Diagnostic Results. , 2019, , 161-178.		0
67	The use of cytological material in melanoma for programmed death ligand 1 immunostaining. Cytopathology, 2019, 30, 61-67.	0.4	5
68	Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Modern Pathology, 2018, 31, 1036-1045.	2.9	60
69	Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations. Cancer Cytopathology, 2018, 126, 342-352.	1.4	102
70	Social media expands the reach of the 2017 ASC Annual Meeting. Journal of the American Society of Cytopathology, 2018, 7, 219-223.	0.2	6
71	Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. Cancer Cytopathology, 2018, 126, 406-413.	1.4	33
72	Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. Journal of Surgical Oncology, 2018, 117, 678-684.	0.8	16

#	Article	IF	CITATIONS
73	Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1127-1133.	1.2	73
74	Rapid On-Site Evaluation of Endobronchial Ultrasound–Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 253-262.	1.2	116
75	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 408-419.	1.2	70
76	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. European Journal of Cancer, 2018, 89, 64-71.	1.3	3
77	The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma. Journal of the American Society of Cytopathology, 2018, 7, 324-332.	0.2	14
78	Advances in Molecular Testing Techniques in Cytologic Specimens. Surgical Pathology Clinics, 2018, 11, 669-677.	0.7	8
79	The transcription factor Foxp1 preserves integrity of an active Foxp3 locus in extrathymic Treg cells. Nature Communications, 2018, 9, 4473.	5.8	29
80	Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genetics, 2018, 226-227, 17-22.	0.2	1
81	Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. Journal of Neuropathology and Experimental Neurology, 2018, 77, 628-635.	0.9	57
82	Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Modern Pathology, 2017, 30, 499-508.	2.9	116
83	Utility of BRCA1â€associated protein 1 immunoperoxidase stain to differentiate benign versus malignant mesothelial proliferations in cytologic specimens. Diagnostic Cytopathology, 2017, 45, 312-319.	0.5	12
84	The professional Twitter account: creation, proper maintenance, and continuous successful operation. Diagnostic Cytopathology, 2017, 45, 621-628.	0.5	13
85	A Twitter primer: Dos and don'ts for cytopathologists. Diagnostic Cytopathology, 2017, 45, 577-579.	0.5	9
86	Big data from small samples: Informatics of nextâ€generation sequencing in cytopathology. Cancer Cytopathology, 2017, 125, 236-244.	1.4	6
87	Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 960-965.	0.7	27
88	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	1.4	58
89	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience, 2017, 4, 47-56.	0.9	21
90	Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget, 2017, 8, 10845-10857.	0.8	14

#	Article	IF	CITATIONS
91	Exercise-induced haemoptysis as a rare presentation of a rare lung disease. Thorax, 2016, 71, 865-868.	2.7	O
92	Cytology Specimens: A Goldmine for Molecular Testing. Archives of Pathology and Laboratory Medicine, 2016, 140, 1189-1190.	1.2	35
93	Optimizing the <scp>DNA</scp> yield for molecular analysis from cytologic preparations. Cancer Cytopathology, 2016, 124, 254-260.	1.4	49
94	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1267-1272.	1.2	95
95	Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 341-344.	1.2	107
96	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. Diagnostic Cytopathology, 2016, 44, 1000-1009.	0.5	55
97	Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1281-1284.	1.2	26
98	Survival rates in T1 and T2 gastric cancer: A Western report. Journal of Surgical Oncology, 2016, 114, 602-606.	0.8	16
99	Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 4332-4337.	0.7	98
100	Preanalytic Variables in Cytology: Lessons Learned From Next-Generation Sequencingâ€"The MD Anderson Experience. Archives of Pathology and Laboratory Medicine, 2016, 140, 1191-1199.	1.2	115
101	Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 825-829.	1.2	64
102	Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. American Journal of Clinical Pathology, 2016, 145, 222-237.	0.4	91
103	Next-generation sequencing of central nervous systems tumors: the future of personalized patient management. Neuro-Oncology, 2016, 18, 308-310.	0.6	6
104	Quantitative Real-Time PCR: Recent Advances. Methods in Molecular Biology, 2016, 1392, 161-176.	0.4	64
105	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget, 2016, 7, 76362-76373.	0.8	22
106	Pancreatic neuroendocrine tumor masquerading as metastasis in a patient with esophageal cancer: Diagnosis by endoscopic ultrasound-guided fine-needle aspiration. Journal of Digestive Endoscopy, 2016, 07, 080-082.	0.1	O
107	Factors affecting the success of nextâ€generation sequencing in cytology specimens. Cancer Cytopathology, 2015, 123, 659-668.	1.4	127
108	Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers, 2015, 7, 2023-2036.	1.7	107

#	Article	IF	CITATIONS
109	The role of cytology in the era of HPV-related head and neck carcinoma. Seminars in Diagnostic Pathology, 2015, 32, 250-257.	1.0	20
110	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	3.2	70
111	Role of cystathionine $\hat{l}^2$ -synthase in human breast Cancer. Free Radical Biology and Medicine, 2015, 86, 228-238.	1.3	125
112	Longâ€term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. Journal of Surgical Oncology, 2015, 111, 875-881.	0.8	25
113	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 144, 713-721.	0.4	34
114	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clinical Genitourinary Cancer, 2015, 13, e19-e26.	0.9	18
115	Adrenocorticotropic hormoneâ€producing thymic neuroendocrine carcinoma with oncocytic features: A case report and review of literature. Diagnostic Cytopathology, 2015, 43, 329-334.	0.5	1
116	Beyond BRAF V600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.3	138
117	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	0.8	45
118	Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers, 2015, 7, 1699-1715.	1.7	107
119	Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research, 2014, 20, 6336-6345.	3.2	70
120	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. Science Translational Medicine, 2014, 6, 249ra111.	5.8	285
121	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clinical Breast Cancer, 2014, 14, 468-474.	1.1	29
122	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388.	1.1	50
123	Prevalence, Clinicopathologic Associations, and Molecular Spectrum of <i>ERBB2</i> ( <i>HER2</i> ) Tyrosine Kinase Mutations in Lung Adenocarcinomas. Clinical Cancer Research, 2012, 18, 4910-4918.	3.2	407